Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury,391033.shtml

<p>Results show promising neurological recovery in severely-injured, acute cervical spinal cord injury patients treated with Cethrin HOPKINTON, Mass., May 12</p> <p>HOPKINTON, Mass., May 12 /PRNewswire-FirstCall/ — Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI.&nbsp; The trial…</p>